{{Rsnum
|rsid=908867
|Chromosome=11
|position=27724217
|Orientation=minus
|GMAF=0.07943
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 23.0 | 76.1
| HCB | 0.0 | 4.4 | 95.6
| JPT | 0.0 | 11.5 | 88.5
| YRI | 0.7 | 18.4 | 81.0
| ASW | 1.8 | 21.1 | 77.2
| CHB | 0.0 | 4.4 | 95.6
| CHD | 0.0 | 1.8 | 98.2
| GIH | 8.9 | 42.6 | 48.5
| LWK | 0.9 | 22.7 | 76.4
| MEX | 0.0 | 6.9 | 93.1
| MKK | 1.9 | 16.7 | 81.4
| TSI | 0.0 | 15.7 | 84.3
| HapMapRevision=28
}}

[[rs908867]] is a SNP near the brain-derived neurotrophic factor [[BDNF]] gene.

In a study of , the [[rs908867]] was associated with [[antidepressant]] response, with heterozygote carriers showing a better response than homozygotes.{{PMID|17505499}}

However, a critique of this study was published {{PMID|18781861}}, indicating that this finding should be viewed as preliminary until more research is conducted for several reasons, to wit, "First, the study included not only major depression but also bipolar disorder patients; second, various antidepressants were used in this study, which could affect patients' responses; third, the frequency of the haplotype associated with treatment response is rare; and fourth, previous studies of the effects of single BDNF polymorphisms on antidepressant action have reported conflicting findings."

{{PMID Auto
|PMID=21188787
|Title=Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder
}}

{{PMID|19589503}} A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder.

{{PMID|21172166|OA=1
}} Pharmacogenetics of antidepressant response.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}